India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 689.42 billion. The enterprise value is 830.83 billion.
| Market Cap | 689.42B |
| Enterprise Value | 830.83B |
Important Dates
The next confirmed earnings date is Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Jul 3, 2026 |
Share Statistics
Biocon has 1.62 billion shares outstanding. The number of shares has increased by 14.22% in one year.
| Current Share Class | 1.62B |
| Shares Outstanding | 1.62B |
| Shares Change (YoY) | +14.22% |
| Shares Change (QoQ) | +18.58% |
| Owned by Insiders (%) | 45.96% |
| Owned by Institutions (%) | 23.83% |
| Float | 801.81M |
Valuation Ratios
The trailing PE ratio is 150.96 and the forward PE ratio is 54.49. Biocon's PEG ratio is 0.78.
| PE Ratio | 150.96 |
| Forward PE | 54.49 |
| PS Ratio | 4.07 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 13.20 |
| P/FCF Ratio | 351.57 |
| P/OCF Ratio | 34.57 |
| PEG Ratio | 0.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.09, with an EV/FCF ratio of 423.68.
| EV / Earnings | 215.46 |
| EV / Sales | 4.91 |
| EV / EBITDA | 23.09 |
| EV / EBIT | 49.04 |
| EV / FCF | 423.68 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.22 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 4.29 |
| Debt / FCF | 78.71 |
| Interest Coverage | 1.76 |
Financial Efficiency
Return on equity (ROE) is 1.15% and return on invested capital (ROIC) is 3.04%.
| Return on Equity (ROE) | 1.15% |
| Return on Assets (ROA) | 1.73% |
| Return on Invested Capital (ROIC) | 3.04% |
| Return on Capital Employed (ROCE) | 3.42% |
| Weighted Average Cost of Capital (WACC) | 5.83% |
| Revenue Per Employee | 10.29M |
| Profits Per Employee | 234,450 |
| Employee Count | 16,447 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.21 |
Taxes
In the past 12 months, Biocon has paid 791.00 million in taxes.
| Income Tax | 791.00M |
| Effective Tax Rate | 17.66% |
Stock Price Statistics
The stock price has increased by +7.22% in the last 52 weeks. The beta is 0.32, so Biocon's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +7.22% |
| 50-Day Moving Average | 422.88 |
| 200-Day Moving Average | 390.58 |
| Relative Strength Index (RSI) | 49.33 |
| Average Volume (20 Days) | 6,704,373 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 169.27 billion and earned 3.86 billion in profits. Earnings per share was 2.82.
| Revenue | 169.27B |
| Gross Profit | 102.66B |
| Operating Income | 16.94B |
| Pretax Income | 4.48B |
| Net Income | 3.86B |
| EBITDA | 35.31B |
| EBIT | 16.94B |
| Earnings Per Share (EPS) | 2.82 |
Balance Sheet
The company has 38.83 billion in cash and 154.34 billion in debt, with a net cash position of -115.51 billion or -71.32 per share.
| Cash & Cash Equivalents | 38.83B |
| Total Debt | 154.34B |
| Net Cash | -115.51B |
| Net Cash Per Share | -71.32 |
| Equity (Book Value) | 366.22B |
| Book Value Per Share | 210.14 |
| Working Capital | 31.11B |
Cash Flow
In the last 12 months, operating cash flow was 19.94 billion and capital expenditures -17.98 billion, giving a free cash flow of 1.96 billion.
| Operating Cash Flow | 19.94B |
| Capital Expenditures | -17.98B |
| Depreciation & Amortization | 18.36B |
| Net Borrowing | -46.69B |
| Free Cash Flow | 1.96B |
| FCF Per Share | 1.21 |
Margins
Gross margin is 60.65%, with operating and profit margins of 10.01% and 2.28%.
| Gross Margin | 60.65% |
| Operating Margin | 10.01% |
| Pretax Margin | 2.65% |
| Profit Margin | 2.28% |
| EBITDA Margin | 20.86% |
| EBIT Margin | 10.01% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 17.35% |
| Buyback Yield | -14.22% |
| Shareholder Yield | -14.10% |
| Earnings Yield | 0.56% |
| FCF Yield | 0.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Biocon is 423.70, which is -0.54% lower than the current price. The consensus rating is "Buy".
| Price Target | 423.70 |
| Price Target Difference | -0.54% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 13.74% |
| EPS Growth Forecast (3Y) | 33.79% |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Biocon has an Altman Z-Score of 1.84 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 8 |